A 38-year-old white male taxi driver was referred to a lipid clinic by his general practitioner for management of combined hyperlipidemia. He was a smoker with a 20 pack-year history. His father had died of myocardial infarction at age 55 years. Examination of this patient revealed a blood pressure of 136/99 mmHg and a body mass index of 29 kg/m2, with no clinical signs of hyperlipidemia.
Student Discussion Document (pdf)
Mehdi Mirzazadeh,1* Negar Maghsoodi,2 and Jeffrey Barron3
1Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford, UK; 2Department of Chemical Pathology, St, Helier Hospital, Carshalton, UK; 3Biochemistry Department, Labtests, Penrose, Auckland, New Zealand.
*Address correspondence to this author at: Department of Clinical Biochemistry, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX5 1NS, UK. Fax +44-1865-220348; E-mail Mehdi.email@example.com.
A 38-year-old white male taxi driver was referred to a lipid clinic by his general practitioner for management of combined hyperlipidemia. He was a smoker with a 20 pack-year history. His father had died of myocardial infarction at age 55 years. Examination of this patient revealed a blood pressure of 136/99 mmHg and a body mass index of 29 kg/m2, with no clinical signs of hyperlipidemia. Cholesterol testing revealed a total serum cholesterol value of 251 mg/dL (6.5 mmol/L; reference interval, 3.7–7.0 mmol/L), an HDL concentration of 30.9 mg/dL (0.8 mmol/L; reference interval, 0.7–1.8mmol/L), and triglycerides of 539 mg/dL (6.1 mmol/L; reference interval, <1.7 mmol/L), results consistent with metabolic syndrome. The patient’s calculated 10-year cardiovascular risk was ˃20%, indicative for primary prevention of hyperlipidemia with a statin, after changes in lifestyle (1). Baseline biochemical investigations before starting the statin showed a serum creatine kinase (CK)4 activity of 889 U/L (reference interval,24–195 U/L) and an alanine aminotransferase activity of 61 U/L (reference interval, <50 U/L). The results of other tests were within their respective reference intervals: total bilirubin, 0.8 mg/dL (13 μmol/L; reference interval, <14 μmol/L); alkaline phosphatase, 95 U/L (reference interval, <150 U/L); and γ-glutamyltransferase, 49 U/L (reference interval,<50 U/L). The results of other laboratory investigations (including renal function, blood count, serum vitamin B12, folate, serum protein electrophoresis, antinuclear antibodies, C-reactive protein, and thyroid function) were normal. At 30 years of age, the patient’s mother had been diagnosed with lower limb muscle weakness, which made her unable to dorsiflex her feet. His 48-year-old brother and 38-year-old maternal half-brother were both fine. On questioning, the patient admitted to a weekend of heavy physical activity before the test but had no other major complaints.
- Joint British Societies. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1–52.
Questions to Consider
- What conditions can cause increased serum CK?
- What other testing would be useful to help determine the cause of the increased CK?
- Given this patient’s family history, what condition should be considered to explain the mothers’symptoms and the patient’s increased CK?
Final Publication and Comments
The final published version with discussion and comments from the experts appears
in the February 2014 issue of Clinical Chemistry, approximately 3-4 weeks after the Student Discussion is posted.
If you are associated with an educational center and would like to receive the cases and
questions 3-4 weeks in advance of publication, please email firstname.lastname@example.org.
AACC is pleased to allow free reproduction and distribution of this Clinical Case
Study for personal or classroom discussion use. When photocopying, please make sure
the DOI and copyright notice appear on each copy.
Copyright © 2014 American Association for Clinical Chemistry